Vistin Pharma ASA : Proposal for Extraordinary Dividend


09.10.17 14:35
Meldung
 
Vistin Pharma ASA : Proposal for Extraordinary Dividend

Oslo, Norway, 9 October 2017

Norwegian pharmaceutical company Vistin Pharma ASA ("Vistin Pharma") announced today that the Board of Vistin Pharma will propose an extraordinary dividend of NOK 7.00 per share.

On 2 October, the Company announced the successful completion of the sale of its opioids and tablet manufacturing business to TPI Enterprises Limited, which resulted in the receipt of a provisional cash consideration of NOK 159.5 million. The sale is expected to have a positive net cash effect of NOK 140 - 150 million, before any transaction costs. As a result of this sale, the Board will call for an extraordinary general meeting to approve a dividend of NOK 7.00 per share (NOK 119.4 million).

Following the sale, Vistin Pharma is a pure play metformin producer, with a strong position in the global metformin market. The global market for metformin is expected to grow by four to five percent per annum, and Vistin Pharma is attractively positioned to capture part of this growth. The Company's project to double the production capacity for metformin is progressing according to plan, and the project will be presented in further details in the third quarter financial report to be released on 27 October.

For further information, please contact:

Kjell-Erik Nordby

CEO

+47 91 36 42 80

kjell-erik.nordby@vistin.com

Gunnar Manum

CFO

+47 95 17 91 90

gunnar.manum@vistin.com 

 
 
 
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.





This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Vistin Pharma ASA via Globenewswire




 

Breaking News


Kurs- und weitere Informationen zum Thema:

VISTIN PHARMA ASA NK 1

Aktuelle Diskussionen zum Thema:


Aktuelle Nachrichten zum Unternehmen:


Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

VISTIN PHARMA ASA NK 1
Weitere Meldungen
 
09.10 Vistin Pharma ASA : Propo.
09.10 Net Insight AB: Net Insight .
09.10 Cargotec's financial informat.
09.10 Ad hoc: Holmes Investment .
09.10 Ad hoc: Correction of a rele.
09.10 Ad hoc: SAF-HOLLAND S.A.
09.10 Stolt-Nielsen Limited Reports.
09.10 Ad hoc: DIC Asset AG pla.
09.10 SCOR estimates the cost o.
06.10 New large TITANĀ® order fo.
06.10 Ad hoc: Holmes Investment .
06.10 Ageas and Norges Bank: Tr.
06.10 Ad hoc: Klarstellung: Überna.
06.10 Klövern AB (publ): Klövern .
06.10 Karo Pharma AB completes.
06.10 Ad hoc: RWE Aktiengesells.
06.10 Curetis kündigt Teilnahme an.
06.10 Curetis to Present at Key I.
06.10 Metso appoints three Busine.
06.10 Vaisala's Interim Report Jan.
06.10 Scatec Solar closes financin.
06.10 Wentworth Resources Limite.
05.10 MPLX LP to announce 2017.
05.10 Marathon Petroleum Corp. to.
05.10 Ad hoc: OHB SE: Europäisc.
05.10 EQS-Adhoc: Kapitalerhöhung.
05.10 Ad hoc: OTI Greentech AG.
05.10 Sanofi : Appellate Court Ord.
05.10 Ad hoc: Pfeiffer Vacuum T.
05.10 Final result of the voluntary.


Umfrage
 
Welche Social Networks nutzen Sie meistens?
Facebook
keine
Twitter
Xing
Linked in
Youtube
myspace
Google+
Wikipedia
andere


Stimmen: 34581 , Ergebnis


Kurssuche
Status: nicht eingeloggt

Registrieren | Passwort vergessen?
 
 
Im Bereich Nachrichten:
Nordex SE: Nächste Aufwärtswelle gestartet?
Experte: Stefan Hofmann, STOCK-WORLD
Kolumnen
DAX DOW ist das ...
Thomas Heydrich, Systemstradings.de (20.04.18)
Experte: Thomas Heydrich, Systemstradings.de
DAX kommt trotz ...
CMC Markets, (20.04.18)
Experte: CMC Markets,
Schweizer Franken – zurück ...
Feingold-Research, (20.04.18)
Experte: Feingold-Research,
DAX vor neuem Sprung?
Christian Zoller, www.boerse-daily.de (20.04.18)
Experte: Christian Zoller, www.boerse-daily.de
Zucker: Keine Wende in ...
Jürgen Sterzbach, boerse-daily.de (20.04.18)
Experte: Jürgen Sterzbach, boerse-daily.de
Dax Anleger halten sich ...
Cornelia Frey, Börse Stuttgart AG (20.04.18)
Experte: Cornelia Frey, Börse Stuttgart AG
Facebook: Was erwarten ...
Volker Gelfarth, (20.04.18)
Experte: Volker Gelfarth,
Steinhoff-Anleihen: Eine ...
Robert Sasse, (20.04.18)
Experte: Robert Sasse,
Bundes- / Staatsanleihen
Sabine Traub, Börse Stuttgart AG (20.04.18)
Experte: Sabine Traub, Börse Stuttgart AG
Facebook vor und nach ...
Max Otte, (20.04.18)
Experte: Max Otte,
Nordex SE: Nächste ...
Stefan Hofmann, STOCK-WORLD (20.04.18)
Experte: Stefan Hofmann, STOCK-WORLD
Gold vor der Entscheidung
Sven Weisenhaus, Stockstreet GmbH (20.04.18)
Experte: Sven Weisenhaus, Stockstreet GmbH
Niquet's World
Neues vom Portal
 
Wie uns das Internet das Vergleichen so einfach wie nie zuvor macht
Letzte Börsen-Meldung
 
Letzte Börsen-Analyse
 
Top-Klicks News
 
Top-Klicks Analysen